This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (7)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Endocrine Diseases  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

Larry I. Lipshultz, MD; Edward D. Kim, MD

JAMA. 1999;281:465-466.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Sildenafil citrate represents the most recent advance for the treatment of organic erectile dysfunction. The first effective pill for erectile dysfunction, this type 5-phosphodiesterase inhibitor has enjoyed tremendous popularity in its first year of availability. In an earlier double-blinded, placebo-controlled study, an overall 70% to 80% improvement in erections was reported in a mixed population of patients with both organic and psychogenic causes of erectile dysfunction.¹ However, because of sildenafil's relatively recent introduction, detailed analyses of its effects in subgroups of patients with specific causes of erectile dysfunction have been few in number.

The association between diabetes mellitus and erectile dysfunction is well established.² Approximately 35% to 75% of men with diabetes have erectile dysfunction, and these numbers could be even larger if milder degrees of erectile impairment were considered. Fortunately, treatment options have advanced significantly during the last 10 to 15 . . . [Full Text of this Article]

Author Affiliations: From the Division of Male Reproductive Medicine and Surgery and Scott Department of Urology (Drs Lipshultz and Kim), Baylor College of Medicine, Houston, Tex.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Sildenafil for Treatment of Erectile Dysfunction in Men With Diabetes: A Randomized Controlled Trial
Marc S. Rendell, Jacob Rajfer, Pierre A. Wicker, Michael D. Smith, and for the Sildenafil Diabetes Study Group
JAMA. 1999;281(5):421-426.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Erectile dysfunction in patients with diabetes mellitus -- advances in treatment with phosphodiesterase type 5 inhibitors
Snow
British Journal of Diabetes & Vascular Disease 2002;2:282-287.
ABSTRACT